number and title for this Federal Register document. The general policy for comments and other submissions from members of the public is to make these submissions available for public viewing on the Internet at http://www.regulations.gov as they are received without change, including any personal identifiers or contact information. Any associated form(s) for this collection may be located within this same electronic docket and downloaded for review/testing. Follow the instructions at http://www.regulations.gov for submitting comments. Please submit comments on any given form identified by docket number, form number, and title.

FOR FURTHER INFORMATION CONTACT: To request more information on this proposed information collection or to obtain a copy of the proposal and associated collection instruments, please write to the Naval Health Research Center, Deployment Health Research Department, ATTN: LCDR Rachel Lee, 140 Sylvester Rd., San Diego, CA 92106–3521 or call (619) 553–8983.

SUPPLEMENTARY INFORMATION:

Title; Associated Form; and OMB Number: ACAM2000® Myopericarditis Registry; OMB Control Number 0720–0054.

Needs and Uses: The information collection requirement is necessary to address Food and Drug Administration requirements to establish several Phase IV post-licensure studies to evaluate the long-term safety of ACAM2000® smallpox vaccine. Among the required post-licensure studies is the establishment of a myopericarditis registry. The ACAM2000® Myopericarditis Registry is designed to study the natural history of myopericarditis following receipt of the ACAM2000® vaccine, including evaluating factors that may influence disease prognosis, thus addressing the FDA post-licensure requirement and ensuring the continued licensing of this vaccine.

Affected Public: Individuals or households; federal government.

Annual Burden Hours: 10.

Number of Respondents: 10.

Responses per Respondent: 2.

Average Burden per Response: 30 minutes.

Frequency: Semi-annually.

Eligible respondents are civilians who are former Active Duty or active Guard/Reserve in the U.S. Military that received the ACAM2000® smallpox vaccine while in the military and subsequently developed signs or symptoms of myopericarditis. The information collected will illuminate the natural history of post-vaccine myopericarditis and evaluate factors that may influence disease prognosis. Inclusion of civilians who were formerly in the military in addition to current military members is imperative in order to obtain information on those who may have separated from the military due to their medical condition. Conducting this Registry will ensure the continued licensure of this military relevant vaccine.

Dated: June 25, 2015.

Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 2015–16014 Filed 6–29–15; 8:45 am]
BILLING CODE 5001–06–P

DEPARTMENT OF DEFENSE

Office of the Secretary

[Transmittal No. 15–41]

36(b)(1) Arms Sales Notification


ACTION: Notice.

SUMMARY: The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104–164 dated July 21, 1996.

FOR FURTHER INFORMATION CONTACT: Ms. B. English, DSCA/DBO/CFM, (703) 601–3740.

The following is a copy of a letter to the Speaker of the House of Representatives, Transmittal 15–41 with attached Policy Justification and Sensitivity of Technology.

Dated: June 24, 2015.

Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
The Honorable John A. Boehner  
Speaker of the House  
U.S. House of Representatives  
Washington, DC 20515

Dear Mr. Speaker:

Pursuant to the reporting requirements of Section 36(b)(1) of the Arms Export Control Act, as amended, we are forwarding herewith Transmittal No. 15-41, concerning the Department of the Navy’s proposed Letter(s) of Offer and Acceptance to Australia for defense articles and services estimated to cost $69 million. After this letter is delivered to your office, we plan to issue a press statement to notify the public of this proposed sale.

Sincerely,

J. W. Rixey  
Vice Admiral, USN  
Director

Enclosures:  
1. Transmittal  
2. Policy Justification  
3. Sensitivity of Technology

Transmittal No. 15–41
Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended

(i) **Prospective Purchaser:** Australia
(ii) **Total Estimated Value:**

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Defense Equipment</td>
<td>$35 million</td>
</tr>
<tr>
<td>Sustainment</td>
<td>34 million</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$69 million</strong></td>
</tr>
</tbody>
</table>

(iii) **Description and Quantity or Quantities of Articles or Services under Consideration for Purchase:** up to fourteen (14) AGM–88B High Speed Anti-Radiation Missiles (HARM) Tactical Missiles, sixteen (16) AGM–88E Advanced Anti-Radiation Guided Missiles (AARGM) Tactical Missiles, four (4) CATM–88B Captive Air Training Missiles, eight (8) CATM–88E Advanced Anti-Radiation Guided Missiles (AARGM) Captive Air Training Missiles, six (6) AARGM Guidance Sections, five (5) AARGM Control Sections, and two (2) AARGM Tactical Telemetry Missiles (for live fire testing), containers, spares and repair parts, support equipment, publications and technical documentation, personnel training and training equipment, U.S. Government and contractor engineering, technical, and logistics support services, and other elements of logistics and program support.

(iv) **Military Department:** Navy (AZN, Amendment #1)

(v) **Prior Related Cases:** FMS case AZN-$37M–12June2013

(vi) **Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:** None

(vii) **Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:** See Attached Annex
The proposed sale is consistent with US foreign policy and national security objectives as outlined in the policy justification of the notification.

5. All defense articles and services listed in this transmittal have been authorized for release and export to Australia.

There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.

Transmittal No. 15–41
Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended

Annex
Item No. vii

(vii) Sensitivity of Technology:

1. The AGM–88E Advanced Anti-Radiation Guided Missile (AARGM) weapon system is an air-to-ground missile system intended to suppress or destroy land or sea-based radar emitters associated with enemy air defenses and provides tactical air forces with a lethal countermeasure to enemy radar directed, surface-to-air missiles, and air defense artillery weapons systems. Destruction or suppression of enemy radars denies the enemy the use of air defense systems, thereby improving the survivability of our tactical aircraft. It uses a multimode seeker that incorporates global positioning system/inertial measurement unit (GPS/IMU) midcourse guidance, a radio frequency (RF) radiation homing receiver, an active millimeter wave seeker, an Integrated Broadcast Service Receiver (IBS–R) and a Weapons Impact Assessment (WIA) transmitter. The AARGM AGM–88E when assembled is classified Secret. The AARGM Guidance Section (seeker hardware) and Control Section with the Target Detector is classified Confidential.

2. The AGM–88 High Speed Anti-Radiation Missiles (HARM) weapon system is an air-to-ground missile system intended to suppress or destroy land or sea-based radar emitters associated with enemy air defenses and provides tactical air forces with a lethal countermeasure to enemy radar directed, surface-to-air missiles, and air defense artillery weapons systems. Destruction or suppression of enemy radars denies the enemy the use of air defense systems, thereby improving the survivability of our tactical aircraft. The AGM–88B HARM when assembled is classified Confidential. The HARM Guidance Section (seeker hardware), and Control Section with the Target Detector are classified Confidential. The HARM Control Section with the Target Detector is classified Confidential.

3. If a technologically advanced adversary were to obtain knowledge of the specific hardware and software elements of this possible sale, the information could be used to develop countermeasures which might reduce weapon system effectiveness or be used in the development of a system with similar or advanced capabilities.

4. A determination has been made that the Government of Australia can provide substantially the same degree of protection for the technology being released as the US Government. The sale is necessary in furtherance of the US foreign policy and national security objectives as outlined in the policy justification of the notification.